Galaxy Surfactants earnings beat lifts margin guidance amid broad-based volume recovery

Investment View and Valuation

Motilal Oswal Financial Services reiterated its BUY recommendation on Galaxy Surfactants following a strong Q1 FY27 earnings beat, supported by broad-based volume recovery, favourable product mix and operating leverage. The broker set a target price of Rs 3,160, based on 25 times FY28E EPS, compared with a CMP of Rs 2,508.

Motilal Oswal raised its FY27 and FY28 earnings estimates by 22 per cent and 15 per cent, respectively, after management increased its full-year EBITDA per tonne guidance.

Q1 FY27 Financial Performance

Galaxy Surfactants reported consolidated Q1 FY27 gross sales of Rs 17.8 billion, up 39 per cent year on year and ahead of Motilal Oswal's estimate of Rs 15.0 billion. Consolidated volume increased 5 per cent year on year, with contributions from both Performance Surfactants and Specialty Care.

EBITDA per tonne rose 77 per cent year on year to about Rs 35,458, aided by US Specialty performance, premium-specialty momentum, disciplined pricing and operating leverage.

Volume Recovery and Geographic Performance

India volumes grew 11 per cent year on year and 18 per cent quarter on quarter, marking a return to double-digit growth after nearly two years. Management attributed the improvement to a broad-based recovery among Tier-1 and non-Tier-1 customers, normalisation of reformulation-related disruptions and resilient rural demand.

Management expects domestic momentum to continue, supported by the festive season, Tier-1 recovery, elevated alcohol prices, GST 2.0 and stronger rural consumption. Revenue from India, Rest of World and AMET rose 36 per cent, 48 per cent and 33 per cent year on year to about Rs 7.6 billion, Rs 6.4 billion and Rs 3.7 billion, respectively. Performance Surfactants accounted for 66 per cent of revenue, compared with 65 per cent in Q1 FY26.

Internationally, AMET volume declined 4 per cent year on year but grew 18 per cent sequentially as West Asia disruptions eased. Rest of World delivered mid-single-digit growth, led by Asia-Pacific and improving North American demand after US tariff rationalisation.

Growth Outlook and Management Guidance

The Mexico project remains on track for commercialisation over the next 12 months, which management expects to support stronger regional growth. Management retained its full-year volume-growth guidance of 6–8 per cent and raised EBITDA per tonne guidance to Rs 24,000–25,000 from Rs 19,000–21,000. Capex is expected to be about Rs 1.5 billion, while several new product launches are planned in Q2 FY27.

Motilal Oswal expects Galaxy Surfactants to deliver FY26–28 revenue, EBITDA and adjusted PAT CAGR of 14 per cent, 23 per cent and 27 per cent, respectively, with volume CAGR of 8 per cent. The broker's growth thesis rests on the following drivers:

• R&D and innovation
• Domestic Tier-1 recovery
• An AMET rebound
• Expanding global operations
• The new-product pipeline

Key Risks and Watch Items

• Continued feedstock volatility
• Geopolitical disruption in West Asia
• Potential moderation in EBITDA per tonne from elevated Q1 FY27 levels as favourable mix and near-term tailwinds taper